EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PARP Inhibition Shifts Murine Myeloid Cells Toward a More Tolerogenic Profile In Vivo

Jose R Pittaluga-Villarreal, Casey M Daniels, Tara Capece, Pauline R Kaplan, Martin Meier-Schellersheim, Aleksandra Nita-Lazar iD

Biomolecules · 2025

DOI: 10.3390/biom15081149 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Jose R Pittaluga-Villarreal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Functional Cellular Networks Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases (NIAID), National In…. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Phthalazines, Myeloid Cells, Piperazines. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Division of Intramural Research, NIAID, NIH, Intramural Research Program of the National Institutes of Health (NIH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The human Poly ADP-ribose Polymerase (PARP) family comprises 17 enzymes responsible for the transfer of ADP-ribose to proteins, forming poly- or mono-ADP-ribosylation. This post-translational modification regulates DNA repair and programmed cell death, processes affecting cancer biology. PARP inhibitors, including the FDA-approved olaparib, are used to treat BRCA-dependent breast and ovarian cancers. Although therapies with use of PARP inhibitors are showing clinical success, their effects on the immune system remain understudied. Prior work has shown that PARP inhibition can modulate inflammatory responses and alter innate immunity. In this study, we evaluated the immunomodulatory effects of olaparib on myeloid cells in vivo, focusing on bone marrow and spleen. Olaparib treatment altered the composition and activation state of dendritic cells, neutrophils, and macrophages. In the bone marrow, olaparib increased the proportion of cDC2 population, mature neutrophils and inflammatory macrophages expressing CD80. In contrast, splenic myeloid cells exhibited enhanced expression of markers associated with tolerogenic phenotypes, including CD206 and CD124 in neutrophils and macrophages. The spleen also showed an increase in immature monocyte-derived dendritic cells (CD206+) and a bias toward the cDC2 subset. These findings indicate that PARP inhibition can induce short-term phenotypic remodeling of myeloid cell populations, promoting a more immunoregulatory profile, especially in the spleen. These changes may contribute to an altered immune landscape with implications for anti-tumor immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsPhthalazinesMyeloid CellsPiperazinesImmune ToleranceAnimalsMiceSpleenDendritic CellsMice, Inbred C57BLNeutrophilsPoly(ADP-ribose) PolymerasesMacrophagesFemaleHumans

Stichwörter der Autor:innen

M2 macrophagesN2 neutrophilsPARP inhibitorsdendritic cellsimmunosuppressionimmunotherapymacrophagesmyeloid cellsneutrophilsolaparib

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsolaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerases

Autor:innen und Institutionen

  • Functional Cellular Networks Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892-1892, USA.
  • Computational Biology Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892-1892, USA.

ORCID-Profile: Aleksandra Nita-Lazar

Förderung

  • Division of Intramural Research, NIAID, NIH
  • Intramural Research Program of the National Institutes of Health (NIH)

Zitieren

APA

Pittaluga-Villarreal, J. R., Daniels, C. M., Capece, T., Kaplan, P. R., Meier-Schellersheim, M., & Nita-Lazar, A. (2025). PARP Inhibition Shifts Murine Myeloid Cells Toward a More Tolerogenic Profile In Vivo. Biomolecules. https://doi.org/10.3390/biom15081149

Vancouver

Pittaluga-Villarreal JR, Daniels CM, Capece T, Kaplan PR, Meier-Schellersheim M, Nita-Lazar A. PARP Inhibition Shifts Murine Myeloid Cells Toward a More Tolerogenic Profile In Vivo. Biomolecules. 2025. doi:10.3390/biom15081149

BibTeX
@article{PittalugaVillarreal2025,
  author = {Pittaluga-Villarreal, Jose R and Daniels, Casey M and Capece, Tara and Kaplan, Pauline R and Meier-Schellersheim, Martin and Nita-Lazar, Aleksandra},
  title = {PARP Inhibition Shifts Murine Myeloid Cells Toward a More Tolerogenic Profile In Vivo},
  journal = {Biomolecules},
  year = {2025},
  doi = {10.3390/biom15081149}
}
Kostenlos starten →